Cover Image
市場調查報告書

原發性血小板過多症:開發中產品分析

Essential Thrombocythemia - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 229782
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
原發性血小板過多症:開發中產品分析 Essential Thrombocythemia - Pipeline Review, H1 2018
出版日期: 2018年04月17日 內容資訊: 英文 83 Pages
簡介

原發性血小板過多症(Essential thrombocythemia)是一種慢性骨髓增生之罕見疾病,最常見的症狀有頭痛及頭暈、手足有刺痛般疼痛、沒感覺、或相反的有灼燒般疼痛。主要的治療方法為藥物療法及緊急時使用血小板單采術。

本報告提供原發性血小板過多症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

原發性血小板過多症概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的治療藥
  • 企業開發中的產品

原發性血小板過多症:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

原發性血小板過多症的治療藥開發企業

  • Aop Orphan Pharmaceuticals AG
  • F. Hoffmann-La Roche Ltd
  • Galena Biopharma Inc
  • Incyte Corp
  • Italfarmaco SpA
  • MEI Pharma Inc
  • PharmaEssentia Corp

藥物簡介

原發性血小板過多症:暫停中的計劃

原發性血小板過多症:開發中止的產品

原發性血小板過多症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10358IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Pipeline Review, H1 2018, provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape.

Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech and transient ischemic attacks.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Essential Thrombocythemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Essential Thrombocythemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Essential Thrombocythemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 3, 4 and 2 respectively.

Essential Thrombocythemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Essential Thrombocythemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Essential Thrombocythemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Essential Thrombocythemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Essential Thrombocythemia (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Essential Thrombocythemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Essential Thrombocythemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Essential Thrombocythemia - Overview
  • Essential Thrombocythemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Essential Thrombocythemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Essential Thrombocythemia - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Aop Orphan Pharmaceuticals AG
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Italfarmaco SpA
  • MEI Pharma Inc
  • PharmaEssentia Corp
  • SELLAS Life Sciences Group Inc
  • Essential Thrombocythemia - Drug Profiles
  • anagrelide hydrochloride CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • anagrelide hydrochloride PR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • givinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • idasanutlin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • peginterferon alfa-2a - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pracinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ropeginterferon alfa-2b - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ruxolitinib phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veliparib ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Essential Thrombocythemia - Dormant Projects
  • Essential Thrombocythemia - Discontinued Products
  • Essential Thrombocythemia - Product Development Milestones
  • Featured News & Press Releases
  • Nov 15, 2017: Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi) for the Treatment of Essential Thrombocythemia
  • Nov 01, 2017: Incyte Highlights Jakafi Data at 59th Annual ASH Meeting
  • Dec 28, 2016: Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)
  • Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
  • Jun 13, 2016: Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
  • Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
  • Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance
  • Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting
  • May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Essential Thrombocythemia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Essential Thrombocythemia - Pipeline by AbbVie Inc, H1 2018
  • Essential Thrombocythemia - Pipeline by Aop Orphan Pharmaceuticals AG, H1 2018
  • Essential Thrombocythemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Essential Thrombocythemia - Pipeline by Incyte Corp, H1 2018
  • Essential Thrombocythemia - Pipeline by Italfarmaco SpA, H1 2018
  • Essential Thrombocythemia - Pipeline by MEI Pharma Inc, H1 2018
  • Essential Thrombocythemia - Pipeline by PharmaEssentia Corp, H1 2018
  • Essential Thrombocythemia - Pipeline by SELLAS Life Sciences Group Inc, H1 2018
  • Essential Thrombocythemia - Dormant Projects, H1 2018
  • Essential Thrombocythemia - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Essential Thrombocythemia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top